Document Detail

Antifibrinolytic agents and desmopressin as hemostatic agents in cardiac surgery.
MedLine Citation:
PMID:  11573859     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To review the use of systemic hemostatic medications for reducing bleeding and transfusion requirements with cardiac surgery. DATA SOURCES: Articles were obtained through computerized searches involving MEDLINE (from 1966 to September 2000). Additionally, several textbooks containing information on the diagnosis and management of bleeding associated with cardiac surgery were reviewed. The bibliographies of retrieved publications and textbooks were reviewed for additional references. STUDY SELECTION: Due to the large number of randomized investigations involving systemic hemostatic medications for reducing bleeding associated with cardiac surgery, the article selection process focused on recent randomized controlled trials, metaanalyses and pharmacoeconomic evaluations. DATA EXTRACTION: The primary outcomes extracted from the literature were blood loss and associated transfusion requirements, although other outcome measures such as mortality were extracted when available. DATA SYNTHESIS: Although the majority of investigations for reducing cardiac bleeding and transfusion requirements have involved aprotinin, evidence from recent meta-analyses and randomized trials indicates that the synthetic antifibrinolytic agents, aminocaproic acid and tranexamic acid, have similar clinical efficacy. Additionally, aminocaproic acid (and to a lesser extent tranexamic acid) is much less costly. More comparative information of hemostatic agents is needed retative to other outcomes (eg., reoperation rates, myocardial infarction, stroke). There is insufficient evidence to recommend the use of desmopressin for reducing bleeding and transfusion requirements in cardiac surgery, although certain subsets of patients may benefit from its use. CONCLUSIONS: Of the medications that have been used to reduce bleeding and transfusion requirements with cardiac surgery, the antifibrinolytic agents have the best evidence supporting their use. Aminocaproic acid is the least costly therapy based on medication costs and transfusion requirements.
B L Erstad
Related Documents :
19365279 - Differences among low-molecular-weight heparins: evidence in patients with acute corona...
18657679 - Platelet inhibitor therapy: current perspectives and emerging novel agents: introduction.
11720639 - Dalteparin for acute coronary syndromes.
11010749 - Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secon...
7545449 - Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in pati...
21060749 - Clinical benefit of low molecular weight heparin for st-segment elevation myocardial in...
8478719 - Estimation of left ventricular mass and infarct size from nitrogen-13-ammonia pet image...
20132499 - Transthoracic sensor for noninvasive assessment of left ventricular contractility: vali...
17939329 - Percutaneous coronary intervention versus coronary artery bypass grafting in patients w...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  35     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-09-27     Completed Date:  2002-02-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1075-84     Citation Subset:  IM    
Department of Pharmacy Practice & Science, College of Pharmacy, Tucson, AZ 85721-0207, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aminocaproic Acids / therapeutic use
Antifibrinolytic Agents / adverse effects,  therapeutic use*
Aprotinin / economics,  therapeutic use
Blood Loss, Surgical / prevention & control*
Critical Care
Deamino Arginine Vasopressin / adverse effects,  therapeutic use*
Heart Diseases / surgery
Hemostatics / adverse effects,  therapeutic use*
Meta-Analysis as Topic
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Aminocaproic Acids; 0/Antifibrinolytic Agents; 0/Hemostatics; 16679-58-6/Deamino Arginine Vasopressin; 9087-70-1/Aprotinin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mediators of chronic heart failure: how drugs work.
Next Document:  Is more than one quinolone needed in clinical practice?